Medically refractory epilepsy remains a significant clinical challenge, affecting approximately 30 percent of the 3.4 million Americans living with epilepsy.
Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.
New study reveals that epigenetic age predictions fluctuate significantly throughout the day, emphasizing the need to consider timing in aging assessments.